AutoGenomics and McKesson Medical-Surgical Inc. Enter into Distribution Agreement
AutoGenomics enters into Distribution Agreement with McKesson Medical-Surgical Inc. to distribute AutoGenomics' proprietary INFINITI Systems and reagents.
- San Diego, CA (1888PressRelease) December 04, 2015 - AutoGenomics, Inc., a leader in providing automated molecular testing solutions, announced today that it has entered into an agreement whereby McKesson Medical-Surgical Inc. and AutoGenomics will jointly distribute the AutoGenomics' INFINITIŽ molecular diagnostic systems and related reagent and consumables products throughout the United States.
AutoGenomics' molecular diagnostics proprietary technology platform is in use globally in clinical reference laboratories, contract research organizations (CRO's), specialty clinics and hospital laboratories. The platform consists of a family of INFINITIŽ analyzers including the INFINITIŽ PLUS, a prepared sample to answer system, and the INFINITIŽ High Throughput System, which has the capability of producing over 6,000 patient results per day. The platform also includes five FDA cleared tests and a menu of over 60 genetic tests for potential application in the areas of personalized medicine (pain management, cardiovascular health assessment and mental health therapy), women's health, oncology, infectious diseases and genetic disorders.
McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation, offers healthcare products and distribution services, solutions and clinical support to a wide range of healthcare providers including physicians' offices, hospitals and clinical reference laboratories.
"We believe that our partnership with McKesson Medical-Surgical Inc., with its extensive distribution network, will broaden the market for our INFINITIŽ platform and related genetic tests as healthcare in the United States enters the era of Precision Medicine," said Fareed Kureshy, President and Chief Executive Officer of AutoGenomics.
About AutoGenomics
AutoGenomics Inc., a privately held company based in Vista, CA, developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and oncology. With the discovery of genes and their link to various disease states, the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine. For more information, visit http://www.autogenomics.com.
About McKesson Medical-Surgical Inc.
McKesson Medical-Surgical Inc., with offices in Richmond, Va., is an affiliate of McKesson Corporation. McKesson Corporation, currently ranked 11th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. McKesson Medical-Surgical works with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam